Johnson & Johnson (JNJ) Said to Settle Risperdal Case on First Day; Shares Move Higher
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Price: $148.53 -0.69%
Overall Analyst Rating:
NEUTRAL (
Up)
Dividend Yield: 3.3%
Revenue Growth %: -13.4%
Overall Analyst Rating:
NEUTRAL (
Up)Dividend Yield: 3.3%
Revenue Growth %: -13.4%
Join SI Premium – FREE
Shares of Johnson & Johnson (NYSE: JNJ) are higher Monday following headlines that it settled Risperdal case on the first day of trial.
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
The data comes from a confidential statement announced in a Philadelphia court.
Shares are up 0.5 percent in morning trade.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Upgrades Johnson & Johnson (JNJ) to Buy, 'Steady outlook, low expectations'
- Texas Instruments (TXN) jumps on first above-consensus guide in seven years
- Johnson & Johnson upgraded to Buy at HSBC on 'asymmetric risk and attractive upside'
Create E-mail Alert Related Categories
FDA, Insiders' Blog, LitigationSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
